Pia Österlund

Om mig
Publikationer
Populärvetenskap och samverkan

Om mig

Adjungerad professor i kolorektalcancer vid institutionen för
onkologi-patologi från 1 februari 2021. Primär anställning: Läkare vid
Karolinska Universitetssjukhuset respektive Tampere Universitetssjukhus. För
mer information, se den engelska profilsidan.

Artiklar

Article: ACTA ONCOLOGICA. 2024;63:248-258
Detailed analysis of metastatic colorectal cancer patients who developed cardiotoxicity on another fluoropyrimidine and switched to S-1 treatment (subgroup analysis of the CardioSwitch-study)
Kinos S; Hagman H; Halonen P; Soveri L-M; O'Reilly M; Pfeiffer P; Froedin J-E; Sorbye H; Heerva E; Liposits G; Kallio R; Algars A; Ristamaki R; Salminen T; Barlund M; Shah C-H; Mcdermott R; Rockert R; Flygare P; Kwakman J; Teske AJ; Punt C; Glimelius B; Osterlund P
Article: CANCERS. 2024;16(5):1052
Impact of Primary Tumor Location on Demographics, Resectability, Outcomes, and Quality of Life in Finnish Metastatic Colorectal Cancer Patients (Subgroup Analysis of the RAXO Study)
Aho S; Osterlund E; Ristimaki A; Nieminen L; Sundstrom J; Makinen MJ; Kuopio T; Kytola S; Algars A; Ristamaki R; Heerva E; Kallio R; Halonen P; Soveri L-M; Nordin A; Uutela A; Salminen T; Stedt H; Lamminmaki A; Muhonen T; Kononen J; Glimelius B; Isoniemi H; Lehto JT; Lehtomaki K; Osterlund P
Article: INTERNATIONAL JOURNAL OF CANCER. 2024;154(3):488-503
Atypical (non-V600E) BRAF mutations in metastatic colorectal cancer in population and real-world cohorts
Osterlund E; Ristimaki A; Makinen MJ; Kytola S; Kononen J; Pfeiffer P; Soveri L-M; Keinanen M; Sorbye H; Nunes L; Salminen T; Nieminen L; Uutela A; Halonen P; Algars A; Sundstrom J; Kallio R; Ristamaki R; Lamminmaki A; Stedt H; Heerva E; Kuopio T; Sjoblom T; Isoniemi H; Glimelius B; Osterlund P
Article: CLINICAL NUTRITION ESPEN. 2023;57:364-374
Time to act!-A cross-sectional study on how nutritional risk increases during hospitalization and associates with worse outcome
Orell H; Pohju A; Tuokkola J; Junttila K; Heikkila A; Osterlund P; Schwab U; Makitie A
Article: CANCERS. 2023;15(13):3398
Association between Computed Tomography-Determined Loss of Muscle Mass and Impaired Three-Month Survival in Frail Older Adults with Cancer
Tolonen A; Kerminen H; Lehtomaki K; Huhtala H; Barlund M; Osterlund P; Arponen O
Article: JOURNAL OF CLINICAL MEDICINE. 2023;12(10):3541
Resectability, Resections, Survival Outcomes, and Quality of Life in Older Adult Patients with Metastatic Colorectal Cancer (the RAXO-Study)
Lehtomaki K; Soveri L-M; Osterlund E; Lamminmaki A; Uutela A; Heerva E; Halonen P; Stedt H; Aho S; Muhonen T; Algars A; Salminen T; Kallio R; Nordin A; Aroviita L; Nyandoto P; Kononen J; Glimelius B; Ristamaki R; Isoniemi H; Osterlund P
Article: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2023;24(7):6753
Transient Changes in Serum CEA, CA19-9, CRP, YKL-40, and IL-6 during Adjuvant Chemotherapy and Survival of Patients with Colorectal Cancer
Lehtomaki K; Heerva E; Kellokumpu-Lehtinen P-L; Mustonen H; Salminen T; Joensuu H; Hermunen K; Boisen MK; Johansen JS; Haglund C; Osterlund P
Article: ESMO OPEN. 2023;8(2):101199
Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer
Punt CJA; Heinemann V; Maughan T; Cremolini C; Van Cutsem E; McDermott R; Bodoky G; Andre T; Osterlund P; Teske AJ; Pfeiffer P
Article: JOURNAL OF GERIATRIC ONCOLOGY. 2023;14(1):101408
Prognostic value of baseline functional status measures and geriatric screening in vulnerable older patients with metastatic colorectal cancer receiving palliative chemotherapy-The randomized NORDIC9-study
Liposits G; Ryg J; Skuladottir H; Winther SB; Moller S; Hofsli E; Shah C-H; Poulsen LO; Berglund A; Qvortrup C; Osterlund P; Glimelius B; Sorbye H; Pfeiffer P
Article: ANNALS OF ONCOLOGY. 2023;34(1):10-32
Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Cervantes A; Adam R; Rosello S; Arnold D; Normanno N; Taieb J; Seligmann J; De Baere T; Osterlund P; Yoshino T; Martinelli E
Article: CANCERS. 2022;14(24):6238
Associations between Response to Commonly Used Neo-Adjuvant Schedules in Rectal Cancer and Routinely Collected Clinical and Imaging Parameters
Karimi M; Osterlund P; Hammarstroem K; Imam I; Frodin J-E; Glimelius B
Article: JOURNAL OF CLINICAL MEDICINE. 2022;11(19):5603
The Prognostic Value of Pre-Treatment Circulating Biomarkers of Systemic Inflammation (CRP, dNLR, YKL-40, and IL-6) in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy-The Randomized NORDIC9-Study
Liposits G; Skuladottir H; Ryg J; Winther SB; Moller S; Hofsli E; Shah C-H; Poulsen LO; Berglund A; Qvortrup C; Osterlund P; Johansen JS; Glimelius B; Sorbye H; Pfeiffer P
Article: BRITISH JOURNAL OF CANCER. 2022;127(4):686-694
Resectability, conversion, metastasectomy and outcome according to RAS and BRAF status for metastatic colorectal cancer in the prospective RAXO study
Uutela A; Osterlund E; Halonen P; Kallio R; Algars A; Salminen T; Lamminmaki A; Soveri L-M; Ristamaki R; Lehtomaki K; Stedt H; Heerva E; Muhonen T; Kononen J; Nordin A; Ovissi A; Kytola S; Keinanen M; Sundstrom J; Nieminen L; Makinen MJ; Kuopio T; Ristimaki A; Isoniemi H; Osterlund P
Article: HEALTHCARE. 2022;10(9):1618
How Can the EU Beating Cancer Plan Help in Tackling Lung Cancer, Colorectal Cancer, Breast Cancer and Melanoma?
Horgan D; Baird A-M; Middleton M; Mihaylova Z; Van Meerbeeck JP; Vogel-Claussen J; Van Schil PE; Malvehy J; Ascierto PA; Dube F; Zaiac M; Lal JA; Kaminska-Winciorek G; Donia M; Andre T; Kozaric M; Osterlund P; Dumitrascu DL; Bertolaccini L
Article: ESMO OPEN. 2022;7(3):100427
Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study
Osterlund P; Kinos S; Pfeiffer P; Salminen T; Kwakman JJM; Frodin J-E; Shah CH; Sorbye H; Ristamaki R; Halonen P; Soveri LM; Heerva E; Algars A; Barlund M; Hagman H; McDermott R; O'Reilly M; Rockert R; Liposits G; Kallio R; Flygare P; Teske AJ; van Werkhoven E; Punt CJA; Glimelius B
Article: CANCERS. 2022;14(7):1713
Health-Related Quality of Life in Metastatic Colorectal Cancer Patients Treated with Curative Resection and/or Local Ablative Therapy or Systemic Therapy in the Finnish RAXO-Study
Lehtomaki K; Stedt HP; Osterlund E; Muhonen T; Soveri L-M; Halonen P; Salminen TK; Kononen J; Kallio R; Algars A; Heerva E; Lamminmaki A; Uutela A; Nordin A; Lehto J; Saarto T; Sintonen H; Kellokumpu-Lehtinen P-L; Ristamaki R; Glimelius B; Isoniemi H; Osterlund P
Article: CANCER TREATMENT AND RESEARCH COMMUNICATIONS. 2022;31:100517
Sex hormones and sperm parameters after adjuvant oxaliplatin-based treatment for colorectal cancer.
Falk P; Severin M; Berglund Å; Guren MG; Hofsli E; Österlund P; Tandberg A; Eberhard J; Sorbye H
Article: FRONTIERS IN NUTRITION. 2022;9:1030619
GLIM in diagnosing malnutrition and predicting outcome in ambulatory patients with head and neck cancer
Orell HK; Pohju AK; Osterlund P; Schwab US; Ravasco P; Makitie A
Article: FRONTIERS IN ONCOLOGY. 2022;12:826073
KRAS-G12C Mutation in One Real-Life and Three Population-Based Nordic Cohorts of Metastatic Colorectal Cancer
Osterlund E; Ristimaki A; Kytola S; Kuopio T; Heerva E; Muhonen T; Halonen P; Kallio R; Soveri L-M; Sundstrom J; Keinanen M; Algars A; Ristamaki R; Sorbye H; Pfeiffer P; Nunes L; Salminen T; Lamminmaki A; Makinen MJ; Sjoblom T; Isoniemi H; Glimelius B; Osterlund P
Article: ESMO OPEN. 2021;6(6):100219
Current landscape of ESMO/ASCO Global Curriculum adoption and medical oncology recognition: a global survey
Cufer T; Kosty M; Osterlund P; Jezdic S; Pyle D; Awada A; Close J; El-Saghir N; Lordick F; Rutkowski P; Tfayli A; Wildiers H
Article: CANCERS. 2021;13(15):3892
Lead Time and Prognostic Role of Serum CEA, CA19-9, IL-6, CRP, and YKL-40 after Adjuvant Chemotherapy in Colorectal Cancer
Lehtomaki K; Mustonen H; Kellokumpu-Lehtinen P-L; Joensuu H; Hermunen K; Soveri L-M; Boisen MK; Dehlendorff C; Johansen JS; Haglund C; Osterlund P
Article: ESMO OPEN. 2021;6(4):100208
Treatment response of colorectal cancer liver metastases to neoadjuvant or conversion therapy: a prospective multicentre follow-up study using MRI, diffusion-weighted imaging and ¹H-MR spectroscopy compared with histology (subgroup in the RAXO trial)
Uutela A; Ovissi A; Hakkarainen A; Ristimaki A; Lundbom N; Kallio R; Soveri LM; Salminen T; Algars A; Halonen P; Ristamaki R; Nordin A; Sequeiros RB; Rinta-Kiikka I; Lantto E; Virtanen J; Paakko E; Liukkonen E; Saunavaara J; Ryymin P; Lammentausta E; Osterlund P; Isoniemi H
Article: BRITISH JOURNAL OF SURGERY. 2021;108(7):817-825
Centralized repeated resectability assessment of patients with colorectalliver metastases during first-line treatment: prospective study
Isoniemi H; Uutela A; Nordin A; Lantto E; Kellokumpu I; Ovissi A; Kosunen J; Kallio R; Soveri LM; Salminen T; Algars A; Lamminmaki A; Halonen P; Ristamaki R; Rasanen J; Karjula H; Vaalavuo Y; Lavonius M; Osterlund P
Article: JCO ONCOLOGY PRACTICE. 2021;17(7):442-e998
Nutrition in Cancer Care: A Brief, Practical Guide With a Focus on Clinical Practice
Liposits G; Orrevall Y; Kaasa S; Osterlund P; Cederholm T
Article: CANCERS. 2021;13(11):2604
Quality of Life in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy-The Randomized NORDIC9-Study
Liposits G; Eshoj HR; Moller S; Winther SB; Skuladottir H; Ryg J; Hofsli E; Shah C-H; Poulsen LO; Berglund A; Qvortrup C; Osterlund P; Glimelius B; Sorbye H; Pfeiffer P
Article: THE LANCET REGIONAL HEALTH. EUROPE. 2021;3:100049
Repeated centralized multidisciplinary team assessment of resectability, clinical behavior, and outcomes in 1086 Finnish metastatic colorectal cancer patients (RAXO): A nationwide prospective intervention study
Osterlund P; Salminen T; Soveri L-M; Kallio R; Kellokumpu I; Lamminmaki A; Halonen P; Ristamaki R; Lantto E; Uutela A; Osterlund E; Ovissi A; Nordin A; Heerva E; Lehtomaki K; Rasanen J; Murashev M; Aroviita L; Jekunen A; Lindvall-Andersson R; Nyandoto P; Kononen J; Lepisto A; Poussa T; Muhonen T; Algars A; Isoniemi H
Article: ACTA ONCOLOGICA. 2020;59(12):1416-1423
Postoperative serum CA19-9, YKL-40, CRP and IL-6 in combination with CEA as prognostic markers for recurrence and survival in colorectal cancer
Hermunen K; Soveri L-M; Boisen MK; Mustonen HK; Dehlendorff C; Haglund CH; Johansen JS; Osterlund P
Article: NUTRIENTS. 2020;12(2):E407-407
Consumption of Lactose, Other FODMAPs and Diarrhoea during Adjuvant 5-Fluorouracil Chemotherapy for Colorectal Cancer.
Holma R; Laatikainen R; Orell H; Joensuu H; Peuhkuri K; Poussa T; Korpela R; Österlund P
Article: ANNALS OF ONCOLOGY. 2020;31(2):246-256
Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group.
André T; Vernerey D; Im SA; Bodoky G; Buzzoni R; Reingold S; Rivera F; McKendrick J; Scheithauer W; Ravit G; Fountzilas G; Yong WP; Isaacs R; Österlund P; Liang JT; Creemers GJ; Rakez M; Van Cutsem E; Cunningham D; Tabernero J; de Gramont A
Article: PLOS ONE. 2020;15(12):e0243900
PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3
Ali AS; Langer SW; Federspiel B; Hjortland GO; Gronbaek H; Ladekarl M; Welin S; Vestermark LW; Arola J; Osterlund P; Knigge U; Sorbye H; Micke P; Grimelius L; Gronberg M; Janson ET
Article: PLOS ONE. 2020;15(11):e0239819
Detection of KRAS mutations in liquid biopsies from metastatic colorectal cancer patients using droplet digital PCR, Idylla, and next generation sequencing
Holm M; Andersson E; Osterlund E; Ovissi A; Soveri L-M; Anttonen A-K; Kytola S; Aittomaki K; Osterlund P; Ristimaki A
Article: PLOS ONE. 2020;15(8):e0236569
Elevated serum YKL-40, IL-6, CRP, CEA, and CA19-9 combined as a prognostic biomarker panel after resection of colorectal liver metastases
Peltonen R; Gramkow MH; Dehlendorff C; Osterlund PJ; Johansen JS; Isoniemi H
Article: SCANDINAVIAN JOURNAL OF SURGERY. 2019;108(3):201-209
Histologically Verified Biliary Invasion was Associated with Impaired Liver Recurrence-Free Survival in Resected Colorectal Cancer Liver Metastases.
Reijonen P; Österlund P; Isoniemi H; Arola J; Nordin A
Article: TRANSLATIONAL ONCOLOGY. 2019;12(8):1122-1130
Two-Week Aflibercept or Erlotinib Administration Does Not Induce Changes in Intestinal Morphology in Male Sprague-Dawley Rats But Aflibercept Affects Serum and Urine Metabolic Profiles
Forsgard RA; Marrachelli VG; Linden J; Fries R; Carmen Collado M; Korpela R; Monleon D; Spillmann T; Osterlund P
Article: THE LANCET GASTROENTEROLOGY AND HEPATOLOGY. 2019;4(5):376-388
Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full- dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial
Whither SB; Liposits G; Skuladottir H; Hofsli E; Shah C-H; Poulsen LO; Ryg J; Osterlund P; Berglund A; Qvortrup C; Glimelius B; Sorbye H; Pfeiffer P
Article: ACTA ONCOLOGICA. 2019;58(4):398-406
Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy.
Soveri LM; Lamminmäki A; Hänninen UA; Karhunen M; Bono P; Osterlund P
Article: FRONTIERS IN NUTRITION. 2019;6:22
Nutritional Counseling for Head and Neck Cancer Patients Undergoing (Chemo) Radiotherapy-A Prospective Randomized Trial
Orell H; Schwab U; Saarilahti K; Osterlund P; Ravasco P; Makitie A
Article: ACTA ONCOLOGICA. 2018;57(6):750-758
Can carcinoembryonic antigen replace computed tomography in response evaluation of metastatic colorectal cancer?
Hermunen K; Lantto E; Poussa T; Haglund C; Österlund P
Article: MEDICAL ONCOLOGY. 2018;35(4):47
Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3)
Ali AS; Gronberg M; Langer SW; Ladekarl M; Hjortland GO; Vestermark LW; Osterlund P; Welin S; Gronbaek H; Knigge U; Sorbye H; Janson ET
Article: TUMOR BIOLOGY. 2018;40(1):1010428317752944-101042831775294
Postoperative CEA is a better prognostic marker than CA19-9, hCGβ or TATI after resection of colorectal liver metastases.
Peltonen R; Österlund P; Lempinen M; Nordin A; Stenman U-H; Isoniemi H
Article: EUROPEAN JOURNAL OF SURGICAL ONCOLOGY. 2017;43(9):1682-1689
Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas
Galleberg RB; Knigge U; Janson ET; Vestermark LW; Haugvik S-P; Ladekarl M; Langer SW; Gronbaek H; Osterlund P; Hjortland GO; Assmus J; Tang L; Perren A; Sorbye H
Article: BMC CANCER. 2017;17(1):548
Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9
Winther SB; Osterlund P; Berglund A; Glimelius B; Qvortrup C; Sorbye H; Pfeiffer P
Article: CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2017;80(2):317-332
Chemotherapy-induced gastrointestinal toxicity is associated with changes in serum and urine metabolome and fecal microbiota in male Sprague-Dawley rats
Forsgard RA; Marrachelli VG; Korpela K; Frias R; Carmen Collado M; Korpela R; Monleon D; Spillmann T; Osterlund P
Article: ACTA OTO-LARYNGOLOGICA. 2017;137(7):778-785
Cachexia at diagnosis is associated with poor survival in head and neck cancer patients
Orell-Kotikangas H; Osterlund P; Makitie O; Saarilahti K; Ravasco P; Schwab U; Makitie AA
Article: BRITISH JOURNAL OF CANCER. 2017;116(10):1271-1278
Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study
Guren TK; Thomsen M; Kure EH; Sorbye H; Glimelius B; Pfeiffer P; Osterlund P; Sigurdsson F; Lothe IMB; Dalsgaard AM; Skovlund E; Christoffersen T; Tveit KM
Article: INTERNATIONAL JOURNAL OF CANCER. 2017;140(4):922-929
EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.
Ålgars A; Sundström J; Lintunen M; Jokilehto T; Kytölä S; Kaare M; Vainionpää R; Orpana A; Österlund P; Ristimäki A; Carpen O; Ristamäki R
Article: PLOS ONE. 2017;12(11):e0187667
Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma
Ali AS; Gronberg M; Federspiel B; Scoazec J-Y; Hjortland GO; Gronbaek H; Ladekarl M; Langer SW; Welin S; Vestermark LW; Arola J; Osterlund P; Knigge U; Sorbye H; Grimelius L; Janson ET
Article: NEUROLOGY. 2016;87(22):2290-2299
FGF21 is a biomarker for mitochondrial translation and mtDNA maintenance disorders
Lehtonen JM; Forsstrom S; Bottani E; Viscomi C; Baris OR; Isoniemi H; Hockerstedt K; Osterlund P; Hurme M; Jylhava J; Leppa S; Markkula R; Helio T; Mombelli G; Uusimaa J; Laaksonen R; Laaksovirta H; Auranen M; Zeviani M; Smeitink J; Wiesner RJ; Nakada K; Isohanni P; Suomalainen A
Article: CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2016;78(4):863-874
Intestinal permeability to iohexol as an in vivo marker of chemotherapy-induced gastrointestinal toxicity in Sprague-Dawley rats
Forsgard RA; Korpela R; Holma R; Linden J; Frias R; Spillmann T; Osterlund P
Article: ANNALS OF ONCOLOGY. 2016;27(8):1386-1422
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.
Van Cutsem E; Cervantes A; Adam R; Sobrero A; Van Krieken JH; Aderka D; Aranda Aguilar E; Bardelli A; Benson A; Bodoky G; Ciardiello F; D'Hoore A; Diaz-Rubio E; Douillard J-Y; Ducreux M; Falcone A; Grothey A; Gruenberger T; Haustermans K; Heinemann V; Hoff P; Köhne C-H; Labianca R; Laurent-Puig P; Ma B; Maughan T; Muro K; Normanno N; Österlund P; Oyen WJG; Papamichael D; Pentheroudakis G; Pfeiffer P; Price TJ; Punt C; Ricke J; Roth A; Salazar R; Scheithauer W; Schmoll HJ; Tabernero J; Taïeb J; Tejpar S; Wasan H; Yoshino T; Zaanan A; Arnold D
Article: ANNALS OF SURGICAL ONCOLOGY. 2016;23(5):1721-1728
Surgical Treatment as a Principle for Patients with High-Grade Pancreatic Neuroendocrine Carcinoma: A Nordic Multicenter Comparative Study
Haugvik S-P; Janson ET; Osterlund P; Langer SW; Falk RS; Labori KJ; Vestermark LW; Gronbaek H; Gladhaug IP; Sorbye H
Article: SUPPORTIVE CARE IN CANCER. 2015;23(6):1495-1502
NRS-2002 for pre-treatment nutritional risk screening and nutritional status assessment in head and neck cancer patients.
Orell-Kotikangas H; Österlund P; Saarilahti K; Ravasco P; Schwab U; Mäkitie AA
Article: THE LANCET ONCOLOGY. 2015;16(5):499-508
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.
Tabernero J; Yoshino T; Cohn AL; Obermannova R; Bodoky G; Garcia-Carbonero R; Ciuleanu T-E; Portnoy DC; Van Cutsem E; Grothey A; Prausová J; Garcia-Alfonso P; Yamazaki K; Clingan PR; Lonardi S; Kim TW; Simms L; Chang S-C; Nasroulah F; RAISE Study Investigators
Article: EUROPEAN JOURNAL OF CANCER. 2014;50(17):2966-2974
Association of adverse events and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil and leucovorin: Is efficacy an impact of toxicity?
Soveri LM; Hermunen K; de Gramont A; Poussa T; Quinaux E; Bono P; André T; Österlund P
Article: NEUROGASTROENTEROLOGY AND MOTILITY. 2014;26(8):1179-1187
Deoxycholic acid induced changes in electrophysiological parameters and macromolecular permeability in murine small intestine with and without functional enteric nervous system plexuses.
Forsgård RA; Korpela R; Stenman LK; Osterlund P; Holma R
Article: CLINICAL CANCER RESEARCH. 2014;20(12):3338-3347
Hsa-miR-31-3p expression is linked to progression-free survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy.
Manceau G; Imbeaud S; Thiébaut R; Liébaert F; Fontaine K; Rousseau F; Génin B; Le Corre D; Didelot A; Vincent M; Bachet J-B; Chibaudel B; Bouché O; Landi B; Bibeau F; Leroy K; Penault-Llorca F; Van Laethem J-L; Demetter P; Tejpar S; Rossi S; Mosakhani N; Osterlund P; Ristamäki R; Sarhadi V; Knuutila S; Boige V; André T; Laurent-Puig P
Article: ONCOLOGY LETTERS. 2014;7(2):553-559
Helicobacter pylori and gastrointestinal symptoms in diagnostics and adjuvant chemotherapy of colorectal cancer
Soveri L-M; Osterlund P; Ruotsalainen T; Poussa T; Rautelin H; Bono P
Article: PLOS ONE. 2014;9(6):e99590
Heterogeneous EGFR gene copy number increase is common in colorectal cancer and defines response to anti-EGFR therapy.
Ålgars A; Avoranta T; Österlund P; Lintunen M; Sundström J; Jokilehto T; Ristimäki A; Ristamäki R; Carpén O
Article: ONCOTARGETS AND THERAPY. 2014;7:1177-1184
A single-institution experience with bevacizumab in the treatment of metastatic colorectal cancer and in conjunction with liver resection.
Osterlund P; Peltonen R; Alanko T; Bono P; Isoniemi H
Article: ANTICANCER RESEARCH. 2013;33(1):253-260
CEA fluctuation during a single fluorouracil-based chemotherapy cycle for metastatic colorectal cancer.
Hermunen K; Haglund C; Osterlund P
Article: JOURNAL OF CLINICAL GASTROENTEROLOGY. 2013;47(1):45-51
Colonic methane production modifies gastrointestinal toxicity associated with adjuvant 5-fluorouracil chemotherapy for colorectal cancer.
Holma R; Korpela R; Sairanen U; Blom M; Rautio M; Poussa T; Saxelin M; Osterlund P
Article: ANNALS OF ONCOLOGY. 2013;24(1):152-160
Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study
Sorbye H; Welin S; Langer SW; Vestermark LW; Holt N; Osterlund P; Dueland S; Hofsli E; Guren MG; Ohrling K; Birkemeyer E; Thiis-Evensen E; Biagini M; Gronbaek H; Soveri LM; Olsen IH; Federspiel B; Assmus J; Janson ET; Knigge U
Article: THE LANCET ONCOLOGY. 2013;14(1):29-37
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.
Bennouna J; Sastre J; Arnold D; Österlund P; Greil R; Van Cutsem E; von Moos R; Viéitez JM; Bouché O; Borg C; Steffens C-C; Alonso-Orduña V; Schlichting C; Reyes-Rivera I; Bendahmane B; André T; Kubicka S; ML18147 Study Investigators
Article: CANCER GENETICS. 2012;205(11):545-551
MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAF.
Mosakhani N; Lahti L; Borze I; Karjalainen-Lindsberg M-L; Sundström J; Ristamäki R; Osterlund P; Knuutila S; Sarhadi VK
Article: HEAD AND NECK. 2012;34(10):1450-1455
High prevalence of vitamin D insufficiency in patients with head and neck cancer at diagnosis
Orell-Kotikangas H; Schwab U; Osterlund P; Saarilahti K; Makitie O; Makitie AA
Article: INTERNATIONAL JOURNAL OF COLORECTAL DISEASE. 2012;27(2):171-178
Colonic methanogenesis in vivo and in vitro and fecal pH after resection of colorectal cancer and in healthy intact colon.
Holma R; Osterlund P; Sairanen U; Blom M; Rautio M; Korpela R
Article: SCANDINAVIAN JOURNAL OF SURGERY. 2012;101(4):275-282
Does preoperative radiotherapy with postoperative chemotherapy increase acute side-effects and postoperative complications of total mesorectal excision? Report of the randomized Finnish rectal cancer trial.
Salmenkylä S; Kouri M; Österlund P; Pukkala E; Luukkonen P; Hyöty M; Pääkkönen M; Mäkelä J; Mustonen H; Järvinen HJ; Finnish Rectal Cancer Trial Group
Article: GENES CHROMOSOMES AND CANCER. 2012;51(1):1-9
MicroRNA profiling differentiates colorectal cancer according to KRAS status.
Mosakhani N; Sarhadi VK; Borze I; Karjalainen-Lindsberg M-L; Sundström J; Ristamäki R; Osterlund P; Knuutila S
Article: BRITISH JOURNAL OF CANCER. 2011;104(4):599-604
Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy.
Österlund P; Soveri L-M; Isoniemi H; Poussa T; Alanko T; Bono P
Article: INTERNATIONAL JOURNAL OF CANCER. 2007;121(9):2052-2059
Temporal trends in the proportion cured for cancer of the colon and rectum:: A population-based study using data from the Finnish Cancer Registry
Lambert PC; Dickman PW; Osterlund P; Andersson T; Sankila R; Glimelius B
Article: BRITISH JOURNAL OF CANCER. 2007;97(8):1028-1034
Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study.
Osterlund P; Ruotsalainen T; Korpela R; Saxelin M; Ollus A; Valta P; Kouri M; Elomaa I; Joensuu H
Article: ACTA ONCOLOGICA. 2005;44(3):203-217
Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: An Acta Oncologica expert report
Nygren P; Sorbye H; Osterlund P; Pfeiffer P
Article: CLINICAL GASTROENTEROLOGY AND HEPATOLOGY. 2004;2(8):696-703
Lactose intolerance associated with adjuvant 5-fluorouracil-based chemotherapy for colorectal cancer.
Osterlund P; Ruotsalainen T; Peuhkuri K; Korpela R; Ollus A; Ikonen M; Joensuu H; Elomaa I
Article: BRITISH JOURNAL OF CANCER. 2002;87(6):591-599
Raltitrexed treatment promotes systemic inflammatory reaction in patients with colorectal carcinoma.
Osterlund P; Orpana A; Elomaa I; Repo H; Joensuu H
Article: ONCOLOGY. 2001;61(2):113-119
A phase I study of raltitrexed (Tomudex) combined with carmofur in metastatic colorectal cancer.
Osterlund P; Elomaa I; Virkkunen P; Joensuu H
Visa fler

Alla övriga publikationer

Letter: JOURNAL OF GERIATRIC ONCOLOGY. 2024;15(2):101632
The effect of BRAF^V600E mutation on survival and treatment efficacy in vulnerable older patients with metastatic colorectal cancer - A post-hoc exploratory analysis of the randomized NORDIC9-studye
Liposits G; Winther SB; Ryg J; Skuladottir H; Moller S; Hofsli E; Shah C-H; Poulsen LO; Berglund A; Qvortrup C; Osterlund P; Glimelius B; Sorbye H; Pfeiffer P
Corrigendum: CLINICAL NUTRITION ESPEN. 2023;58:421-423
Time to act!- A cross-sectional study on how nutritional risk increases during hospitalization and associates with worse (vol 57, pg 364, 2023)
Orell H; Pohju A; Tuokkola J; Junttila K; Heikkila A; Osterlund P; Schwab U; Makitie A
Editorial comment: BRITISH JOURNAL OF SURGERY. 2023;110(8):931-935
Resectability and resection rates of colorectal liver metastases according to RAS and BRAF mutational status: prospective study.
Uutela A; Nordin A; Osterlund E; Halonen P; Kallio R; Soveri L-M; Salminen T; Ålgars A; Ristimäki A; Ovissi A; Lamminmäki A; Muhonen T; Kononen J; Ristamäki R; Heervä E; Stedt H; Lehtomäki K; Kytölä S; Sundström J; Mäkinen MJ; Nieminen L; Kuopio T; Keinänen M; Osterlund P; Isoniemi H; RAXO Study Group
Review: ESMO OPEN. 2023;8(3):101567
The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022
Ducreux M; Abou-Alfa GK; Bekaii-Saab T; Berlin J; Cervantes A; de Baere T; Eng C; Galle P; Gill S; Gruenberger T; Haustermans K; Lamarca A; Laurent-Puig P; Llovet JM; Lordick F; Macarulla T; Mukherji D; Muro K; Obermannova R; O'Connor J-M; O'Reilly EM; Osterlund P; Philip P; Prager G; Ruiz-Garcia E; Sangro B; Seufferlein T; Tabernero J; Verslype C; Wasan H; Van Cutsem E
Other: CASE REPORTS IN ONCOLOGY. 2021;14(3):1475-1482
Metastatic Rectal Carcinoma with Long-Term Remission due to Modern Multimodality Treatment
Eigeliene N; Saarenheimo J; Wichmann V; Osterlund P; Jekunen A
Letter: THE LANCET REGIONAL HEALTH. EUROPE. 2021;5:100135
Lung metastasectomy for colorectal cancer in the PulMiCC randomised controlled trial - Authors' reply
Osterlund P; Isoniemi H
Letter: ACTA ONCOLOGICA. 2020;59(12):1503-1507
An easily adaptable validated risk score predicts cancer-specific survival in stage II colon cancer
Heerva E; Valiaho V; Salminen T; Nieminen L; Carpelan A; Kurki S; Sundstrom J; Huhtinen H; Rantala A; Carpen O; Minn H; Osterlund P; Algars A; Ristamaki R
Editorial comment: SEMINARS IN ONCOLOGY. 2017;44(2):129-131
Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer-A definite conclusion?
Ducreux M; Österlund P; Pignon JP
Letter: JOURNAL OF CLINICAL ONCOLOGY. 2017;35(2):254-255
Global Curriculum Edition 2016: European Society for Medical Oncology/American Society of Clinical Oncology Recommendations for Training in Medical Oncology
Dittrich C; Kosty MP; Jezdic S; Pyle D; Berardi R; Bergh J; El-Saghir NS; Lotz J-P; Osterlund P; Pavlidis N; Purkalne G
Editorial comment: ANNALS OF ONCOLOGY. 2016;27(8):1378-1381
ESMO/ASCO recommendations for a Global Curriculum (GC) in medical oncology-edition 2016
Dittrich C; Kosty M; Jezdic S; Pyle D; Berardi R; Bergh J; El Saghir N; Lotz J-P; Osterlund P; Pavlidis N; Purkalne G
Review: TARGETED ONCOLOGY. 2016;11(3):293-308
A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer.
Loupakis F; Stein A; Ychou M; Hermann F; Salud A; Österlund P
Review: ESMO OPEN. 2016;1(5):e000097
ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016.
Dittrich C; Kosty M; Jezdic S; Pyle D; Berardi R; Bergh J; El-Saghir N; Lotz J-P; Österlund P; Pavlidis N; Purkalne G; Awada A; Banerjee S; Bhatia S; Bogaerts J; Buckner J; Cardoso F; Casali P; Chu E; Close JL; Coiffier B; Connolly R; Coupland S; De Petris L; De Santis M; de Vries EGE; Dizon DS; Duff J; Duska LR; Eniu A; Ernstoff M; Felip E; Fey MF; Gilbert J; Girard N; Glaudemans AWJM; Gopalan PK; Grothey A; Hahn SM; Hanna D; Herold C; Herrstedt J; Homicsko K; Jones DV; Jost L; Keilholz U; Khan S; Kiss A; Köhne C-H; Kunstfeld R; Lenz H-J; Lichtman S; Licitra L; Lion T; Litière S; Liu L; Loehrer PJ; Markham MJ; Markman B; Mayerhoefer M; Meran JG; Michielin O; Moser EC; Mountzios G; Moynihan T; Nielsen T; Ohe Y; Öberg K; Palumbo A; Peccatori FA; Pfeilstöcker M; Raut C; Remick SC; Robson M; Rutkowski P; Salgado R; Schapira L; Schernhammer E; Schlumberger M; Schmoll H-J; Schnipper L; Sessa C; Shapiro CL; Steele J; Sternberg CN; Stiefel F; Strasser F; Stupp R; Sullivan R; Tabernero J; Travado L; Verheij M; Voest E; Vokes E; Von Roenn J; Weber JS; Wildiers H; Yarden Y
Editorial comment: ESMO OPEN. 2016;1(1):e000004
The ESMO/ASCO Global Curriculum and the evolution of medical oncology training in Europe.
Pavlidis N; Alba E; Berardi R; Bergh J; El Saghir N; Jassem J; Kosty M; Lopez R; Lotz J-P; Österlund P; Purkalne G; Dittrich C
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2014;32(3):520
Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first disease progression (PD) in patients with metastatic colorectal cancer (mCRC) previously treated with BEV-based therapy: Outcomes according to KRAS status and first-line CT backbone in the ML18147 study.
Kubicka S; Greil R; Andre T; Bennouna J; Sastre J; Van Cutsem E; Von Moos R; Osterlund PJ; Hegde P; Sersch MA; Osborne S; Hermann F; Arnold D
Review: SCANDINAVIAN JOURNAL OF SURGERY. 2011;100(1):35-41
Surgery combined with oncological treatments in liver metastases from colorectal cancer.
Isoniemi H; Osterlund P
Letter: ANNALS OF ONCOLOGY. 2009;20(2):393-394
Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma.
Bono P; Elfving H; Utriainen T; Osterlund P; Saarto T; Alanko T; Joensuu H

Om mig

Artiklar

Alla övriga publikationer

Nyheter från KI

Kalenderhändelser från KI